Fertility Preservation
37
14
15
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 37 trials
100.0%
+13.5% vs benchmark
11%
4 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (37)
PREgnancy and FERtility Registry
Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone
Ovulation Induction With GnRH Analogue or Dual Trigger?
Decision Aid for Elective Egg Freezing
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
Cryopreservation of Ovarian Tissue
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment
Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment
Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation
Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome
Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Testicular Elastography for Microscopic Testicular Sperm Extraction
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Impact of Gonadotoxic Therapies on Fertility
The Determinants of Fertility Preservation in TRANSgender Patients.
FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients